One study observed that PET-based radiomics combined with tumor stage and age was able to differentiate ALK/ROS1/RET fusion-positive and fusion negative tumors (sensitivity = 0.73, specificity = 0.70) [98]. This evidence concerns the gene ROS1 and neoplasm.